World Wires · story 21968 · unverified · 1 source(s)

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Company Announcement

Open in the desk

Coverage

• Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma GlobeNewswire: public companies · tier D · clear net · 2026-10-05 18:49 UTC

What this site indexes